Adiponectin Expression and the Cardioprotective Role of the Vitamin D Receptor Activator Paricalcitol and the Angiotensin Converting Enzyme Inhibitor Enalapril in ApoE-deficient Mice

Overview

Journal Ther Adv Cardiovasc Dis

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2014 Jul 20

PMID 25037058

Citations 11

Authors

Edu Suarez-Martinez

Kazim Husain

Leon Ferder

Affiliations

Soon will be listed here.

Abstract

Background: Coronary heart disease (CHD) is the number one cause of death in the US. The adipokine adiponectin has been studied intensively for presenting and inversed association with almost every stage of CHD. For instance, the evaluation of molecules capable of enhancing endogenous adiponectin expression is well justified. In this study, we investigated the effect of the vitamin D receptor activator (VDRA) paricalcitol and the angiotensin-converting enzyme inhibitor (ACEI) enalapril on adiponectin expression, lipid profiles, adenosine monophosphate activated protein kinase (AMPK) expression, monocyte chemo-attractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFα),cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), antioxidant capacity, CuZn-superoxide dismutase (CuZn-SOD), Mn-SOD, NADPH p22phox subunits, inducible nitric oxidesynthase (iNOS), endothelial marker eNOS, and 81 atherosclerosis-related genes in ApoE-deficient mice.

Method: Seven-week-old ApoE-deficient mice were treated for 16 weeks as follows: Group 1, ApoE vehicle control (intraperitoneal [i.p.] 100 µl propylene glycol); Group 2, ApoE-paricalcitol (200 ng i.p., 3/week); Group 3, ApoE-Enalapril (30 mg/kg daily); Group 4, ApoE-paricalcitol + enalapril (described dosing); and Group 5, wild-type control (C57BLV).

Results: All treated groups presented significant changes in circulating and cardiac adiponectin, cardiac cholesterol levels, AMPK, MCP-1, TNF-α, COX-2, iNOS, eNOS, CuZn-SOD, Mn-SOD and p22phox. There were 15 genes that differed in their expression, 5 of which are involved in cardioprotection and antithrombotic mechanisms: Bcl2a1a, Col3a1, Spp1 (upregulated), Itga2, and Vwf (downregulated).

Conclusion: Together, our data presented a novel role for VDRA and ACEI in reducing factors associated with CHD that may lead to the discovery of new therapeutic venues.

Citing Articles

Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus.

Mujalli A, Farrash W, Obaid A, Khan A, Almaimani R, Idris S Int J Mol Sci. 2023; 24(24).

PMID: 38139208 PMC: 10743534. DOI: 10.3390/ijms242417380.

Circadian rhythms of risk factors and management in atherosclerotic and hypertensive vascular disease: Modern chronobiological perspectives of an ancient disease.

Geng Y, Smolensky M, Sum-Ping O, Hermida R, Castriotta R Chronobiol Int. 2022; 40(1):33-62.

PMID: 35758140 PMC: 10355310. DOI: 10.1080/07420528.2022.2080557.

Enhanced renoprotective actions of Paricalcitol and omega-3 fatty acids co-therapy against diabetic nephropathy in rat.

El-Boshy M, Alsaegh A, Qasem A, Sindi R, Abdelghany A, Gadalla H J Adv Res. 2022; 38:119-129.

PMID: 35572411 PMC: 9091913. DOI: 10.1016/j.jare.2021.08.010.

Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update.

Gorman S, Weller R Front Cardiovasc Med. 2021; 7:616527.

PMID: 33426009 PMC: 7786057. DOI: 10.3389/fcvm.2020.616527.

Role of Renin-Angiotensin System Components in Atherosclerosis: Focus on Ang-II, ACE2, and Ang-1-7.

Silva G, Franca-Falcao M, Calzerra N, Luz M, Gadelha D, Balarini C Front Physiol. 2020; 11:1067.

PMID: 33013457 PMC: 7494970. DOI: 10.3389/fphys.2020.01067.

References

Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K . Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011; 13(4):401-412. DOI: 10.1016/j.cmet.2011.02.010. View

Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K . Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2005; 188(1):190-5. DOI: 10.1016/j.atherosclerosis.2005.10.034. View

Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber M, Summer R . Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest. 2007; 117(2):375-86. PMC: 1770947. DOI: 10.1172/JCI29709. View

Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher T . Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007; 115(11):1408-16. DOI: 10.1161/CIRCULATIONAHA.106.666941. View

Cuttle L, Nataatmadja M, Fraser J, Kempf M, Kimble R, Hayes M . Collagen in the scarless fetal skin wound: detection with picrosirius-polarization. Wound Repair Regen. 2005; 13(2):198-204. DOI: 10.1111/j.1067-1927.2005.130211.x. View

Peake P, Shen Y, Campbell L, Charlesworth J . Human adiponectin binds to bacterial lipopolysaccharide. Biochem Biophys Res Commun. 2006; 341(1):108-15. DOI: 10.1016/j.bbrc.2005.12.162. View

Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K . Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004; 109(17):2046-9. DOI: 10.1161/01.CIR.0000127953.98131.ED. View

Hopkins T, Ouchi N, Shibata R, Walsh K . Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2006; 74(1):11-8. PMC: 1858678. DOI: 10.1016/j.cardiores.2006.10.009. View

Brasier A . The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010; 86(2):211-8. PMC: 2912657. DOI: 10.1093/cvr/cvq076. View

10.

Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V . Peripheral factors in the metabolic syndrome: the pivotal role of adiponectin. Ann N Y Acad Sci. 2006; 1083:185-95. DOI: 10.1196/annals.1367.013. View

11.

Tardif J, Ponikowski P, Kahan T . Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009; 30(5):540-8. PMC: 2649284. DOI: 10.1093/eurheartj/ehn571. View

12.

Da Cunha V, Tham D, Martin-McNulty B, Deng G, Ho J, Wilson D . Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis. 2004; 178(1):9-17. DOI: 10.1016/j.atherosclerosis.2004.08.023. View

13.

Reddick R, Zhang S, Maeda N . Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb. 1994; 14(1):141-7. DOI: 10.1161/01.atv.14.1.141. View

14.

Liu X, Wu H, Byrne M, Krane S, Jaenisch R . Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A. 1997; 94(5):1852-6. PMC: 20006. DOI: 10.1073/pnas.94.5.1852. View

15.

Wei Y, Lan Y, Liu Y, Meng L, Xu Q, Xie H . [Association of the integrin gene polymorphisms with ischemic stroke and plasma lipid levels]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009; 26(2):211-5. DOI: 10.3760/cma.j.issn.1003-9406.2009.02.021. View

16.

Gannage-Yared M, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G . Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol. 2009; 160(6):965-71. DOI: 10.1530/EJE-08-0952. View

17.

Ouchi N, Shibata R, Walsh K . Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006; 16(5):141-6. PMC: 2749293. DOI: 10.1016/j.tcm.2006.03.001. View

18.

Wang Y, Lam K, Xu J, Lu G, Xu L, Cooper G . Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005; 280(18):18341-7. DOI: 10.1074/jbc.M501149200. View

19.

Motoshima H, Wu X, Mahadev K, Goldstein B . Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004; 315(2):264-71. DOI: 10.1016/j.bbrc.2004.01.049. View

20.

Nimitphong H, Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B . The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance. Endocrine. 2009; 36(2):205-10. DOI: 10.1007/s12020-009-9216-9. View